Werner syndrome (WS) is an autosomal recessive disorder causing symptoms of premature ageing.
Werner syndrome (WS) is an autosomal recessive disorder causing symptoms of premature ageing. 3) In 1996, the Werner syndrome gene (WRN) responsible for WS was identified. 4) The gene product, WRN, acts as a DNA helicase (WRN helicase) with exonuclease activity. 5) WRN greatly participates in DNA metabolism by facilitating cellular processes, including DNA replication, recombination, repair, and transcription in cooperation with other cellular proteins. WRN may participate in the retrovirus replication. 6 ) WS patients lack functional WRN mainly because of mutations that cause premature termination in WRN synthesis, produce incomplete WRN molecules lacking C-terminal nuclear localization signals and so result in impaired nuclear transportation of WRN. 7) The genotoxic clastogen 4-nitroquinoline-1-oxide (4NQO) induces a more distinct increase in both break and interchange aberrations in WS patient cells than in control cells from normal individuals or from patients with other diseases. 8) WS patient lymphoblastoid cell lines (LCLs) transformed by Epstein-Barr virus are hypersensitive to 4NQO than LCLs from normal individuals without mutation. 9) Previously we studied the effect of camptothecin (CPT), a DNA topoisomerase I-trapping agent, on several LCLs from non-WS individuals and WS patients, and showed that CPT had a stronger cytotoxic effect on LCLs from WS patients than LCLs from non-WS individuals. 10) Poot et al. confirmed and extended our results by showing that CPT more strongly impairs S-phase transit in WS LCLs than in normal LCLs.
11) Lebel and Leder made homozygous WS embryonic stem cells (ES) of mice that lacked normal WRN genes at both alleles.
12) Such cells were more markedly sensitive to CPT than were wild-type ES cells.
From these results, we investigated if silencing WRN gene expression by siRNA targeting the WRN gene (WRN-siRNA) increases the sensitivity of cells against CPT. We show here that specific down-regulation of WRN expression increases the cytotoxic effects of CPT in cancer cells, and we discuss the potential of using these findings for cancer therapy.
MATERIALS AND METHODS

Cell Culture and Transfection
HeLa cells were cultured in Dulbecco's modified Eagle's medium (Sigma, St. Louis, MO, U.S.A.) supplemented with 10% fetal calf serum and 25 mg/ml gentamicin (Sigma, St. Louis, MO, U.S.A.). Cells in 100 mm dishes were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
siRNA We preliminarily examined WRN-gene-silencing activity with several siRNA sequences by using down-regulations of WRN mRNA expression as a marker. The design of siRNAs was done according to the method of Elbashir et al. 13) The siRNAs used for silencing the target gene expression consisted of 21 bp duplexes complementary to a unique sequence of the target gene. All these siRNAs had an extra dTdT overhang at their 5Ј ends. Among them, WRN-siRNA with the following sequence was the most effective in silencing WRN expression that suppressed the expression of WRN mRNA by more than 80% in HeLa cells: GUUCUUGU-CACGUCCUCUG targeted against 3373-3391 bases of NM000553. Our intensive homology search by using Smith and Waterman method showed that no other human sequence was identical to this sequence except for the WRN gene. We used this WRN-siRNA in this study. As a negative control, a non-silencing siRNA duplex (NS-siRNA) having sequence 5Ј-UUCUCCGACGUGUCACGUdTdT-3Ј was used. Both of these siRNAs were synthesized by using Qiagen-Xeragon (Germantown, MD, U.S.A.). Transfection of cells with these siRNAs (10 nM) was done by using Oligofectamine (Invitrogen, CA, U.S.A.).
Immunoblotting Cells were washed with ice-cold PBS, were pelleted and then were lysed in a sodium dodecyl sulfate (SDS) buffer containing 1% SDS, 2% beta-mercaptoethanol, 20% glycerol, 30 mM Tris-HCl (pH 6.8), and 0.2 M dithiothreitol. The cell lysate was boiled for 5 min and was electrophoresed on 7.5% SDS-polyacrylamide gels. Proteins fractionated on the gels were electrophoretically transferred to polyvinylidene difluoride membranes (Immobilon, Millipore, MA, U.S.A.) and were blocked overnight with 5% skimmed milk in PBS. Then the membranes were incubated with either anti-WRN (4H12) 14) or anti-b-actin monoclonal antibodies (ICN Biomedicals, Aurora, Ohio, U.S.A.) for 60 min at room temperature, were washed with 0.05% Tween-20 in PBS, were incubated with anti-mouse IgG conjugated with horse radish peroxidase (DakoCytomation, Carpinteria, CA, U.S.A.) and then were washed and developed using an enhanced chemiluminescence reagent (ECL) plus (Amersham Biosciences, U.K.).
Confocal Microscopy HeLa cells cultured at 37°C on microscope cover slips were transfected with 10 nM of NS-or WRN-siRNA, and were cultured further for 30 h. Then the culture medium was replaced with fresh medium containing 10 mM CPT (Sigma, OR, U.S.A.) and the cells were cultured for 6 h. Then, some CPT-treated cells were cultured in the absence of CPT for an additional 3 h to recover from the CPT effect, were fixed with a 3.7% formaldehyde PBS solution at room temperature for 10 min, and then were permeabilized with a 0.1% Triton X-100 PBS solution for 5 min. To detect WRN helicase and replication protein A (RPA), the cells were blocked by incubating in a 3% skimmed milk PBS solution for 60 min and were incubated overnight with primary antibodies (anti-RPA34; Oncogene, Boston, MA, U.S.A.) at 4°C. The slides were washed with 0.05% Tween-20 in PBS three times and were incubated with Alexa Fluor 488-conjugated antibody mouse IgG (Molecular Probes, Eugene, OR, U.S.A.) as a secondary antibody for 60 min at room temperature. Fluorescent images were visualized by using a confocal laser-scanning microscope (Fluoview II; Olympus, Tokyo, Japan).
Cytotoxicity Test To determine the sensitivity to CPT, HeLa cells cultured in 48-well plates were transfected with various doses of siRNA using Oligofectamine. After 24 h, the cells were incubated in Dulbecco's modified Eagle's medium containing various concentrations of CPT. After 48 h (i.e., after 72 h starting from siRNA transfection), the cell viability was measured by using a WST-8 assay (Nacalai Tesque, Kyoto), a modified MTT assay. 15) RESULTS AND DISCUSSION
siRNA-Mediated Suppression of WRN Expression
Immunoblot analysis showed that treatment of HeLa cells with WRN-siRNA for 30 h almost completely suppressed WRN expression, but NS-siRNA added as a negative control did not affect the initial level of WRN (Fig. 1C) . When the effect of 1, 5, 10 nM WRN-siRNAs on the growth of HeLa cells was examined by culturing the transfected cells for 96 h, WRN-siRNA alone weakly suppressed cell viability at these very low concentrations: cell viability was down-regulated by about 20% compared with cells treated with NS-siRNA (Fig. 1A) . This reduction of the viable cell population might be mostly due to a delay in cell cycling as measured by flow cytometry analysis (unpublished observation). However, when WRN-siRNA-treated HeLa cells were incubated with CPT, cell viability was markedly reduced dependent on the dose of WRN-siRNA, and cells treated with NS-siRNA were totally unaffected (Fig. 1B) .
We compared the cytotoxic dose of CPT with HeLa cells treated with 10 nM NS-siRNA and WRN-siRNA by changing the concentrations of CPT (Fig. 2) CPT.
Failure of WRN-Silenced Cells to Recover from DNA Damage Response WRN in the nuclei is mainly in the nucleolus, 14, 16) but it relocates to the nucleoplasm and colocalizes with RPA34 protein to form nuclear foci at the DNA double-strand break points that are generated by genotoxic reagents such as CPT.
17) The RPA34 protein does not bind to duplex DNA, but it binds to the single-strand regions of DNA unwound by DNA helicase for repair. Thus, nuclear foci consisting of WRN or RPA34 or both are assumed to be excellent markers representing damaged DNA loci generated by CPT treatment. Therefore, experiments were done to investigate how down-regulation of WRN affects nuclear RPA34 foci formation and DNA repair during the recovery process of DNA damage (double-strand breaks) caused by CPT. In the absence of CPT, most of WRN was found in the nucleolus while RPA34 was dispersed in the nucleoplasm as reported before 17) (Fig. 3A) . Down-regulation of WRN expression by siRNA treatment, however, made some fraction of RPA34 form nuclear foci in the nucleoplasm (Fig. 3B ). This nuclear relocation of RPA may be interpreted that RPA34 assemble in the legions of endogenous DNA damages which are formed during DNA replication and remain unrepaired due to the absence of WRN in the slightly delayed cell cycle progression as shown in Fig. 1A .
When HeLa cells were treated with CPT for 6 h, many nu- clear foci stained by both anti-WRN and RPA34 antibodies appeared in the nucleoplasm, as we previously reported. 17) The same staining profiles were also obtained with HeLa cells transfected with NS-siRNA used as negative control (Fig. 3C) . Further culture of these cells in the CPT-free medium for 6 h causes most WRN proteins in the nuclear foci to return to the nucleolus leaving fewer numbers and smaller sizes of RPA34 foci on the nucleoplasmic DNA, suggesting that DNA repair was accomplished and that most nuclear foci consisting of WRN and RPA34 disappeared (Fig.  3D) .
Under the same conditions, except the NS-siRNA was replaced by WRN-siRNA, CPT treated HeLa cells maintained many and significantly large RPA34 foci in the nucleoplasm even after removal of CPT at more than 6 h, suggesting that DNA repair was not completed and that the single-strand region was left unrepaired in the RPA34-bound form (Fig. 3E) . It should be noted that most nuclear foci were not stained with WRN antibody as expected from the WRN siRNA treatment, nor was WRN helicase found in the nucleolus because of the silencing of WRN helicase. The data clearly showed that silencing WRN prevented repair of CPT-mediated DNA damages in the CPT-treated HeLa cells, and permitted the accumulation of DNA damage that explained the increased cytotoxicity of CPT in the combined treatment of CPT and WRN-siRNA. Similar effects were observed with cancer cell lines other than HeLa cells (data not shown). The data also explain why WS cells previously showed increased sensitivity to genotoxic reagents, including CPT.
The enzymatic activity of WRN to unwind long duplex DNA substrates is stimulated by RPA, 18) and WRN directly interacts with RPA as verified by co-immunoprecipitation of purified proteins. 19 ) WRN forms nuclear foci in response to genotoxins, including CPT, etoposide, 4NQO and bleomycin. 17) These WRN foci overlap with RPA foci almost entirely and with the foci of Rad51 partially, suggesting cooperative functions of these proteins in response to DNA damage.
The results of this study obtained by using WRN-siRNA at cellular levels were consistent with the following clinical results to treat colorectal cancer patients by using the CPT analogue Irinotecan, commonly used in the clinical setting to treat this tumor type. 20) The WRN function was eliminated in some of the human cancer cells by transcriptional silencing associated with CpG island-promoter hypermethylation. Importantly, WRN gene hypermethylation in colorectal tumors is a predictor of good clinical response to Irinotecan, due to the reduced WRN expression and increased CPT cytotoxicity. These findings highlighted the importance of WRN epigenetic inactivation in human cancer, leading to hypersensitivity to chemotherapeutic drugs.
WRN expression is augmented in rapidly growing cells, such as Epstein-Barr virus-infected and immortalized B limphoblastoid cells, much higher than in virus-infected and mortal B limphoblastoid cells. 21, 22) Also, a wide variety of cancer cells show very high expressions of WRN in the same way as WRN in human fibroblast cells transfected with SV40 T antigen. 21) All these findings imply that many of cancer cells are perhaps "addicted to" (that is, physiologically dependent on) the specifically overexpressed WRN participating in DNA repair to maintain their rapid proliferation, analogously to the theory of cancer cell addiction to certain oncogenes proposed by Weinstein 23) ; these kind of genes and gene products have been pursued as an ideal chemotherapeutic target for anti-cancer agents with few adverse effects. 24) In addition, administration of WRN-siRNA to cancer cells by an appropriate drug delivery system, such as positively charged liposome that are incorporated more efficiently in rapidly growing cancer cells than non-cancerous resting cells, should lower the cytotoxic dose of CPT preferentially in cancer cells, benefiting patients by fewer adverse effects in their normal tissues and cells.
